508 participants
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-06
- Start Date:
- 2026-02-23
- Completion:
- 2028-06-14
Conditions
- Relapsed Refractory Multiple Myeloma
Interventions
- BIOLOGICAL
- DRUG
No Results Yet